Weight-loss shot plus IUD may help reverse womb cancer without surgery
NCT ID NCT07349641
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive both treatments for 26 weeks. The goal is to see if the combination leads to a complete disappearance of abnormal cells, potentially offering a non-surgical option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to predict cancer return in Low-Risk patients
- Could a hormonal IUD replace surgery for some uterine cancers?
- Remote strength training aims to boost endometrial cancer survivorship in rural areas
- New drug combo aims to outsmart Chemo-Resistant ovarian cancer
- New combo therapy shows promise for Tough-to-Treat endometrial cancer
- Do tiny cancer cells in lymph nodes matter? new study aims to find out